913 Shares in Insulet Co. (NASDAQ:PODD) Acquired by CX Institutional

CX Institutional purchased a new position in shares of Insulet Co. (NASDAQ:PODD) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 913 shares of the medical instruments supplier’s stock, valued at approximately $238,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Blue Trust Inc. lifted its position in Insulet by 84.1% during the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 58 shares in the last quarter. Venturi Wealth Management LLC lifted its position in Insulet by 633.3% during the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 133 shares in the last quarter. TD Private Client Wealth LLC lifted its position in Insulet by 32.6% during the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock worth $53,000 after acquiring an additional 56 shares in the last quarter. Friedenthal Financial acquired a new position in Insulet during the 4th quarter worth approximately $57,000. Finally, Versant Capital Management Inc raised its position in shares of Insulet by 106.1% in the 4th quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier’s stock valued at $80,000 after purchasing an additional 157 shares in the last quarter.

Insider Transactions at Insulet

In other news, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the transaction, the executive vice president now owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. This represents a 52.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CAO Lauren Budden sold 915 shares of the company’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the sale, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. This represents a 13.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.47% of the company’s stock.

Analyst Ratings Changes

PODD has been the topic of a number of recent analyst reports. Barclays upped their target price on Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. TD Cowen upped their target price on Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a research report on Friday, January 3rd. Wells Fargo & Company upped their target price on Insulet from $290.00 to $305.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. JPMorgan Chase & Co. upped their target price on Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a research report on Thursday, December 12th. Finally, BTIG Research upped their target price on Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Three investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, Insulet has an average rating of “Moderate Buy” and an average target price of $272.81.

Insulet Price Performance

Shares of PODD opened at $280.35 on Monday. The company has a market cap of $19.67 billion, a P/E ratio of 48.01, a PEG ratio of 3.50 and a beta of 1.22. The stock has a fifty day moving average price of $267.25 and a 200 day moving average price of $235.80. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $282.86.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $0.90 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.13. The firm had revenue of $543.90 million during the quarter, compared to the consensus estimate of $518.50 million. Insulet had a return on equity of 27.98% and a net margin of 21.22%. During the same period in the prior year, the business earned $0.71 EPS. On average, research analysts forecast that Insulet Co. will post 3.22 earnings per share for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.